All News

Omeprazole magnesium, amoxicillin, and rifabutin (Talicia, RedHill Biopharma) is indicated for the treatment of Helicobacter pylori (H. pylori) infection in adults.

Top news of the day from across the health care landscape.

Advancements in the understanding of asthma pathophysiology has led to the discovery of defined asthma phenotypes and targeted interventions involving novel biologic therapies.

Three complement genes identified in a new study may serve as markers for monitoring and predicting the progression and severity of multiple sclerosis.

Although the levels of NDMA that was found through FDA testing are much lower than the levels that a few third-party investigators claimed, the report indicated that these levels exceed what the FDA considers acceptable for these medicines.

A recent study demonstrated that budesonide-formoterol is superior to albuterol for as-needed exacerbation prevention in mild asthma.

EZC Pak, the first physician formulated, tapered immune support pack, will be presented to millionaire and billionaire investors on ABC’s Shark Tank on Sunday, November 3, at 9 PM ET/8 PM CT.

Labeling, seals of approval, and ingredients should be considered when counseling patients about dietary supplements.

Texas oncologist Stephen Hahn, MD, is expected to receive the Trump administration’s nomination for the role of FDA Commissioner, a move that had been anticipated by federal insiders.

The largest ever trial of postoperative radiotherapy in prostate cancer shows men may be spared the procedure after surgery.

Top news of the day from across the health care landscape

The Ensuring Seniors Access to Local Pharmacies Act, which was recently reintroduced, would allow more “preferred” pharmacies in medically underserved areas.

SunGen Pharma, the specialty pharmaceutical company, has received its eighth ANDA approval from the FDA.

Lumacaftor-ivacaftor (Orkambi) improves lung health in patients with cystic fibrosis who tolerate the treatment, but discontinuation rates may pose a risk of deterioration.

Officials from the FDA have allowed ObsEva to begin enrolling patients in IMPLANT 3, the U.S. pivotal Phase 3 clinical trial in nolasiban in women undergoing embryo transfer (ET) following in-vitro fertilization (IVF).

Top news of the day from across the health care landscape

A new computer method could help reveal the origins of Crohn disease and improve early diagnosis and accuracy.

Early treatment with lenalidomide in patients with smoldering multiple myeloma may help delay onset of myeloma-related bone and organ damage.

Stuck at work this Halloween? Gather your coworkers for some truly horrifying pharmacy pet peeves that are sure to keep you up at night.

The FDA Drug Shortages Task Force addressed the root causes of drug shortages and proposed potential solutions.

The injection’s active ingredient, 17α hydroxyprogesterone caproate (also known as 17P), is currently the only approved treatment for pregnant women who have had a prior spontaneous preterm birth.

Top news of the day from across the health care landscape

Men treated with stereotactic ablative radiotherapy found to live significantly longer without any detectable disease progression compared with patients who received no additional treatment.

Patients in a phase 3 study reported better gastrointestinal tolerability with diroximel fumarate (Vumerity) compared with dimethyl fumarate (Tecfidera) in patients with relapsing forms of multiple sclerosis.

A study assessing melanoma cell variability indicates that identifying differences in cell states can be leveraged to improve patient outcomes.

Multiple health care organizations, including The American Hospital Association (AHA), the Institute for Safe Medication Practices (ISMP), and the American Society of Health-System Pharmacists (ASHP), have shown their full support for the MEDS Act.

An ongoing phase 2 study is evaluating SY-1425 plus azacitadine in newly-diagnosed unfit patients with acute myeloid leukemia.

Study suggests that men who use assisted reproduction techniques may benefit from early screening and long-term monitoring for prostate cancer.